Urology Trials

A list of our early phase urology trials which are open to recruitment at University College London Hospitals.

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked IRAS Number, which will take you to the UCLH Find a Study database.

Additional early phase clinical trials recruiting Urology cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.

DURANCE

DURANCE:  A phase Ib/II study to assess the safety and activity of DURvalumab (MEDI4736) in combination with S-488210/S-488211 vAccine in Non-muscle invasive bladder CancEr

IRAS Number263559
Principal Investigator:Prof. Mark Linch
Drug Class/ Treatment:Durvalumab (PD-L1 Blocking IgG1 Kappa Monoclonal Antibody) + S-488210/S-488211 (Peptide Vaccine)
Patient Population:Non-Muscle Invasive Bladder Cancer
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

ABACUS-2

ABACUS-2:  Phase 2 study of neoadjuvant immune checkpoint inhibitors in urothelial cancer

IRAS Number:1003489
Principal Investigator:Prof. Mark Linch
Drug Class/ Treatment:Atezolizumab (IgG1 Isotype Monoclonal Antibody against PD-L1)
Patient Population:

Patient requiring surgery with:

  • Cohort 1: T1 high grade - T4a of the bladder with mixed (dominant) or rare histological subtype
  • Cohort 2: Upper urinary tract (high grade or high risk)
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

Principal Investigator(s):

Mark Linch Profile
Dr. mark linch

Honorary Senior Lecturer & Consultant Medical Oncologist

Anuradha Jayaram Profile Photo
Dr. Anuradha Jayaram

Consultant Medical Oncologist